AstraZeneca PLC
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pascal Claude Roland Soriot
- Full Time Employees
- 96,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge CA United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company dedicated to the discovery, development, production, and worldwide commercialization of innovative prescription medicines. The company maintains a comprehensive portfolio of treatments spanning key therapeutic areas, including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, rare disease, and vaccines and immune therapies. Its innovative products serve a global patient population, reaching over 125 countries through a network of local marketing companies, distributors, and representative offices. The firm's operational focus centers on pioneering scientific breakthroughs to address significant unmet medical needs. AstraZeneca actively invests in research and development, evidenced by substantial annual expenditures aimed at advancing a robust pipeline of next-generation therapies. Recent strategic initiatives include ambitious goals for revenue growth, with an aim to launch 20 new medicines and achieve $80 billion in total revenue by 2030. AstraZeneca consistently engages in strategic partnerships and acquisitions to bolster its capabilities and pipeline. Notable collaborations include an expanded alliance with Harbour BioMed for next-generation biotherapeutics and a research agreement with CSPC Pharmaceutical Group for novel oral drug candidates. The company also recently invested $2 billion in a new Maryland manufacturing facility to establish cell therapy platforms, and its digital health solutions arm, Evinova, was launched in late 2023. Recent product advancements and approvals include Koselugo for neurofibromatosis type 1 in adults and positive Phase III results for Baxdrostat in resistant hypertension. AstraZeneca was established through the merger of Astra AB and Zeneca Group in 1999, and its headquarters are situated in Cambridge, United Kingdom.
Astrazeneca Plc $AZN Shares Sold by Boston Common Asset Management LLC
Astrazeneca Plc $AZN Shares Acquired by DekaBank Deutsche Girozentrale
AI Bubble Risks Make Dividend Stocks Attractive Again
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)
Solis Minerals launches lithium drilling across 800-metre Mandacaru corridor in Brazil
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
ACG Metals beats oxide production target as gold price surges 64%
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
HSBC downgrades AstraZeneca after key trial failure